Diagnosis and clinical features of non-alcoholic fatty liver disease in patients with systemic lupus erythematosus
https://doi.org/10.31146/1682-8658-ecg-176-4-46-53
Abstract
The purpose of the research was to determine the frequency and characterize the course of non-alcoholic fatty liver disease in patients with systemic lupus erythematosus.
Materials and methods. The study included 313 patients with systemic lupus erythematosus, observed in the E. M. Tareev Clinic of Rheumatology, Internal Medicine and Occupational Diseases of I. M. Sechenov First Moscow State Medical University (Sechenov University) in the period from 2001 to 2019. The diagnosis of systemic lupus erythematosus was based on the criteria of the American College of Rheumatology (1997). Examination of all patients included complete blood count, biochemical and immunological blood tests and an abdominal ultrasonography with an assessment of the liver size
and the presence of signs of steatosis. In 5 cases a liver biopsy was performed.
Results. In 33 (10,5%) cases a differential diagnosis was made between non-alcoholic fatty liver disease and lupus hepatitis. Non-alcoholic fatty liver disease was the cause of liver damage in 15 (4,8%) patients with ultrasound signs of liver steatosis. Patients with obesity and metabolic syndrome prevailed in this group, and a low immunological activity of lupus was observed. An increase in liver enzymes in patients with liver steatosis was associated with the use of higher minimum doses of prednisolone.
Conclusion. Ultrasound signs of liver steatosis are an important criterion that suggests non-alcoholic fatty liver disease in patients with systemic lupus erythematosus.
About the Authors
A. P. Panova
Lomonosov Moscow State University
Russian Federation
Russian Federation
postgraduate student, Department of Internal Medicine
Moscow, Russia, 119991, Leninskie Gory, 1
V. G. Avdeev
Lomonosov Moscow State University,
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor of the Department of Internal Medicine, Senior Scientist of the Medical Research and Educational Center
Moscow, Russia, 119991, Leninskie Gory, 1
Moscow, Russia, 119991, Bolshaya Pirogovskaya st., 2–4, 106
T. N. Krasnova
Lomonosov Moscow State University,
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor, Head of the Department of Internal Medicine, Associate Professor of the Department of Internal Medicine, Occupational Diseases and Rheumatology; Senior Research Scientist of the Medical and Educational Center
Moscow, Russia, 119991, Leninskie Gory, 1
Moscow, Russia, 119991, Bolshaya Pirogovskaya st., 2–4, 106
O. A. Georginova
Lomonosov Moscow State University
Russian Federation
Russian Federation
Candidate of Medical Sciences, Assistant Professor of the Department of Internal Medicine
Moscow, Russia, 119991, Leninskie Gory, 1
T. P. Rozina
Lomonosov Moscow State University,
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor of the Department of Internal Medicine, Senior Research Scientist, Head of the Department of Gastroenterology of the Medical Research and Educational Center, Associate Professor of the Department of Internal Medicine, Occupational Diseases and Rheumatology
Moscow, Russia, 119991, Leninskie Gory, 1
Moscow, Russia, 119991, Bolshaya Pirogovskaya st., 2–4, 106
References
1. Liu Y., Yu J., Oaks Z. et al. Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus. ClinImmunol. 2015, Vol.160, no.2, pp. 319–327.
2. Piga M., Vacca A., Porru G. et al. Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis. ClinExpRheumatol. 2010, Vol. 28, no.4, pp.504–510.
3. Chowdhary V.R., Crowson C. S., Poterucha J. J. et al. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol. 2008, Vol. 35, no.11, pp.2159–2164.
4. Takahashi A., Abe K., Saito R. et al. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med. 2013, Vol. 52, no.13, pp. 1461–1465.
5. Matsumoto T., Yoshimine T., Shimouchi K. et al. The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese Autopsy Registry Data. Hum Pathol. 1992, Vol. 23, no.10, pp. 1151–1158.
6. Bessone F., Dirchwolf M., Rodil M. A. et al. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease – a physiopathological and clinical integrated view. Aliment Pharmacol Ther. 2018, Vol. 48, no.9, pp. 892–913.
7. Woods C.P., Hazlehurst J. M., Tomlinson J. W. Glu co corti co ids and non-alcoholic fatty liver disease. J Steroid BiochemMol Biol. 2015, Vol. 154, pp. 94–103.
8. Yu C., Gershwin M. E., Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun. 2014, Vol.48–49, pp.10–13.
9. Petri M., Kim M. Y., Kalunian K. C. et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005, Vol. 353, pp.2550–2558.
10. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005, Vol.112, pp. 2735–2752.
11. Angulo P., Hui J., Marchesini G. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007, Vol. 45, pp. 847–854.
12. Kamata Y., Kamimura T., Yoshio T. et al. Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: a case report.Ryumachi. 2003, Vol. 43, no.4, pp. 667–671.
13. Targher G, Bertolini L, Rodella S et al. Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. ClinEndocrinol (Oxf). 2006. Vol. 64, no.3, pp.337–341.
14. Lettéron P., Brahimi-Bourouina N., Robin M. A. et al. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol. 1997, Vol.272, no.5 Pt 1, pp.1141–1150.
15. Kneeman J.M., Misdraji J., Corey K. E. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012, Vol. 5, no.3, pp. 199–207.
16. Itoh S, Igarashi M, Tsukada Y. et al. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepatogastroenterol (Stuttg).1977, Vol. 24, no.6, pp. 415–418.
17. Nanki T., Koike R., Miyasaka N. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis. Am J Gastroenterol. 1999, Vol. 94, no.11, pp. 3379.
18. Matsumoto T., Yamasaki S., Arakawa A. et al. Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatitis. Pathol Int. 2007, Vol. 57, no.6, pp. 388–389.
19. Shimizu H., Shimizu T., Takahashi D. et al. Corticosteroid dose increase is a risk factor for nonalcoholic fatty liver disease and contralateral osteonecrosis of the femoral head: a case report. BMC Musculoskelet Disord. 2019, Vol. 20, no.1, Р. 88.
20. Dourakis S.P., Sevastianos V. A., Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol. 2002, Vol. 97, no.4, pp. 1074–1075.
21. Todosenko N. M., Koroleva Yu.A., Khaziakhmatova O. G. et al. Genomicandnon-genomic effects of glucocorticoids. Genes & Cells.2017, Vol.XII, no.1, pp.27–33.doi: 10.23868/201703003.
22. Reshetnyak T. M., Seredavkina N. V., Dydykina I. S. et al. Glucocorticoids in the therapy of systemic lupus erythematosus. The Clinician. 2013, Vol.7, no.3–4, pp.14–26.
23. Koorneef L. L., van den Heuvel J. K., Kroon J. et al. Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice. Endocrinology. 2018, Vol. 159, no.12, pp.3925–3936.
24. Kroon J., Koorneef L. L., van den Heuvel J. K. et al. Selective Glucocorticoid Receptor Antagonist CORT125281 Activates Brown Adipose Tissue and Alters Lipid Distribution in Male Mice. Endocrinology. 2018, Vol.159, no.1, pp.535–546.
Review
For citations:
Panova A.P., Avdeev V.G., Krasnova T.N., Georginova O.A., Rozina T.P. Diagnosis and clinical features of non-alcoholic fatty liver disease in patients with systemic lupus erythematosus. Experimental and Clinical Gastroenterology. 2020;174(4):46-53. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-176-4-46-53
Views:
565
Email this article 